

Andrew Senesi is an Associate in Global Innovation within the TechAtlas division of RA Capital Management. Andrew's primary responsibility at RA Capital is to identify and assess orthogonal technologies that intersect the healthcare industry. Andrew holds a PhD in Chemistry from Northwestern University, where he focused on the development of DNA scaffold-based nanoparticle superlattices with novel emergent properties. His postdoctoral work at Argonne National Laboratories involved characterization of nanomaterials using X-ray scattering technologies. Andrew worked previously as an associate at the Chicago Innovation Exchange, an incubator and VC fund associated with the University of Chicago.